Skip to content

Study · In vitro (cells) · 2020

4 results

Evaluation of SS-31 as a Potential Therapeutic Target in the Treatment of Tendinopathy

The source lists no authors.

Orthopaedic journal of sports medicine1 Jul 2020

PMCIDPMC7407841 (opens in a new tab)PepBankPUB-93761426
Read at sourceSource pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In TNF-α-treated human tenocytes, SS‑31 treatment decreased ROS expression.

    In plain wordsIn lab tests on human tendon cells, SS‑31 lowered reactive oxygen species.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseROS in degenerative tenocytes
    Study

    humann: not reported in source

    Human tenocytes with TNF-α (degenerative model)
    Comparator
    Degenerative tenocytes (TNF-α) without SS-31
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    1 mM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    The expression of ROS decreased in the degenerative group after 72 hours of treatment with SS-31.
    2 context sentences
    Summary · context
    Degenerative tenocytes had higher levels of ROS that was decreased with SS-31 treatment.
    Summary · context
    Degenerative group with treatment: cells were treated with 10 ng/ml TNF-α for 72 hours and 1mM SS-31 was added for 72 hours.
  2. 02LabIn vitro (cells)Mechanism

    In TNF-α-treated human tenocytes, SS‑31 treatment brought the raised expression of four mitochondrial genes back close to healthy levels.

    In plain wordsIn lab tests on human tendon cells, SS‑31 returned raised mitochondrial gene activity to near-healthy levels.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial gene expression (FXN, SNRPB, ATP5F1, OPA1)
    Study

    humann: not reported in source

    Human tenocytes with TNF-α (degenerative model)
    Comparator
    Degenerative tenocytes (TNF-α) without SS-31
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    1 mM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    The expression of FXN (iron transport and respiration) and ATP5F1A (ATP synthase) increased significantly in degenerative tenocytes but the expression levels of all 4 genes were close to the healthy tenocyte after SS-31 treatment (Fig 4), suggesting that mitochondrial activity was reduced in degener…
    2 context sentences
    Summary · context
    Expression levels in four mitochondrial genes were upregulated in degenerative tenocytes but normalized by SS-31 treatment.
    Summary · context
    Degenerative group with treatment: cells were treated with 10 ng/ml TNF-α for 72 hours and 1mM SS-31 was added for 72 hours.
  3. 03LabIn vitro (cells)Mechanism

    In TNF-α-treated human tenocytes, SS‑31 treatment decreased the raised expression of the tendon marker Col3.

    In plain wordsIn lab tests on human tendon cells, SS‑31 lowered a raised tendon-matrix gene marker.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCol III expression
    Study

    humann: not reported in source

    Human tenocytes with TNF-α (degenerative model)
    Comparator
    Degenerative tenocytes (TNF-α) without SS-31
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    1 mM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    Col3 and TNMD, tendon-specific gene markers, were higher in degenerative tenocytes and decreased after treatment, suggesting an elevated extracellular matrix remodeling process in tendons under degenerative conditions (Fig 5).
    1 context sentence
    Summary · context
    Degenerative group with treatment: cells were treated with 10 ng/ml TNF-α for 72 hours and 1mM SS-31 was added for 72 hours.
  4. 04LabIn vitro (cells)Mechanism

    In TNF-α-treated human tenocytes, SS‑31 treatment decreased the raised expression of the tendon marker TNMD.

    In plain wordsIn lab tests on human tendon cells, SS‑31 lowered a raised tendon gene marker.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTNMD expression
    Study

    humann: not reported in source

    Human tenocytes with TNF-α (degenerative model)
    Comparator
    Degenerative tenocytes (TNF-α) without SS-31
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    1 mM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    Col3 and TNMD, tendon-specific gene markers, were higher in degenerative tenocytes and decreased after treatment, suggesting an elevated extracellular matrix remodeling process in tendons under degenerative conditions (Fig 5).
    1 context sentence
    Summary · context
    Degenerative group with treatment: cells were treated with 10 ng/ml TNF-α for 72 hours and 1mM SS-31 was added for 72 hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.